Groundbreaking Device Revives Donor Eyeballs, Paving Way for Whole-Eye Transplants

For decades, the transplantation of a whole human eye has remained an elusive dream in medical science. The inherent challenges are immense, ranging from the complexity of the surgical procedure to the rapid degeneration of ocular tissue once removed from the body. Previous attempts have highlighted these difficulties, with transplanted eyes failing to restore sight, underscoring the urgent need for solutions that can maintain the viability of donor organs. However, a glimmer of hope has emerged from researchers who believe they have found a potential breakthrough: a device designed to maintain and revive freshly removed eyeballs using a technique known as perfusion. This method involves supplying surgically-removed organs with the vital oxygen and nutrients they would typically receive inside a living body. Eyes treated with this device exhibit significantly slower degradation, crucially retaining their ability to transmit electrical signals, a prerequisite for vision. This innovation could fundamentally transform the landscape of eye transplantation, making it a viable medical reality. The device, aptly named "Eye-in-a-Care-Box" (ECaBox), was developed by Pia Cosma and her team at the Centre for Genomic Regulation in Spain. It functions by delivering an oxygen-rich fluid supply directly through the artery that normally nourishes the eye with blood. The eye rests on a specialized "bed" within the sealed device, which maintains precise temperature and pressure, while excess fluids are efficiently drained. A transparent window on its side allows researchers to continuously monitor and image the eye, providing invaluable insights into its condition and response. Initial experiments with pig eyes, chosen for their anatomical similarity to human eyes, yielded promising results. While untreated pig eyes rapidly degenerated at room temperature, and even cooling to 4°C offered only marginal preservation for 24 hours, eyes kept within the ECaBox fared remarkably better. After 24 hours, tests confirmed that the perfused eyes were "significantly more viable." Crucially, these treated eyes demonstrated the ability to respond to light, a function lost almost immediately in untreated eyes but restored within 15 minutes of perfusion, with some maintaining this response for over 10 hours. Following the success with porcine models, the team progressed to human eyes. They collected 12 eyes from six deceased donors, treating one eye from each pair with the ECaBox while the other served as a control. Consistent with earlier findings, the perfused human eyes showed superior preservation, particularly of their retinas. Beyond transplantation, Cosma and her colleagues envision their device as a novel platform for studying eye treatments without the ethical complexities of animal experimentation, and with further enhancements, a means to preserve donated human eyes for whole-eye transplantation. While whole-eye transplants have been attempted previously, notably in a recent case at NYU Langone where a patient received an eye along with a face transplant but did not regain sight, the ECaBox offers a new paradigm. The next phase involves developing a portable, surgery-room compatible ECaBox to minimize degradation in eyes from heart-beating donors. As Shannon Tessier of Massachusetts General Hospital notes, the true potential of ECaBox-treated eyes will only be known once actual transplantation trials are conducted, marking an exciting new frontier in ophthalmic medicine.